Novavax Inc (NVAX)

Currency in USD
10.135
-1.055(-9.43%)
Closed·
10.080-0.060(-0.59%)
·
NVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.81011.150
52 wk Range
5.01011.970
Key Statistics
Prev. Close
11.19
Open
11.15
Day's Range
9.81-11.15
52 wk Range
5.01-11.97
Volume
8.72M
Average Volume (3m)
4.72M
1-Year Change
43.5552%
Book Value / Share
-0.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NVAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.000
Upside
+28.27%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Novavax Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Novavax Inc Company Profile

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc Earnings Call Summary for Q4/2025

  • Novavax Q4 2025 EPS of $0.11 beat forecast of -$0.49; revenue hit $147M vs. expected $90.25M, exceeding projections by 62.88%
  • Full-year 2025 revenue reached $1.1B, up 65% YoY, driven by Nuvaxovid sales and partnerships with Sanofi; R&D/SG&A expenses down 42%
  • Cash position strengthened to $857M at year-end 2025, bolstered by $80M in non-dilutive capital received in early 2026
  • Stock rose 1.58% to $9.681 in premarket trading following earnings beat, reflecting positive investor sentiment on operational execution
  • Q1 2026 guidance projects EPS of -$0.33 with $60.4M revenue; company focusing on pipeline advancement and Matrix-M adjuvant expansion
Last Updated: 02/27/2026, 12:12 AM
Read Full Transcript

Compare NVAX to Peers and Sector

Metrics to compare
NVAX
Peers
Sector
Relationship
P/E Ratio
3.7x−3.4x−0.6x
PEG Ratio
0.01−0.160.00
Price/Book
−12.9x3.0x2.6x
Price / LTM Sales
1.5x7.9x3.3x
Upside (Analyst Target)
60.0%92.7%44.5%
Fair Value Upside
Unlock3.1%5.2%Unlock

Analyst Ratings

5 Buy
1 Hold
3 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.000
(+28.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy16.00+57.87%11.00MaintainFeb 27, 2026
Cantor Fitzgerald
Buy18.00+77.60%-MaintainJan 13, 2026
JPMorgan
Sell6.00-40.80%7.00MaintainNov 18, 2025
B.Riley
Buy16.00+57.87%18.00MaintainNov 10, 2025
TD Cowen
Hold7.00-30.93%8.00MaintainNov 04, 2025

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
0.11 / -0.49
Revenue / Forecast
147.00M / 90.25M
EPS Revisions
Last 90 days

NVAX Income Statement

People Also Watch

1,450.79
ASML
-0.89%
37.46
NVO
-0.44%
79.150
ASTS
-7.71%
137.19
PLTR
+0.92%
1,052.20
LLY
+2.95%

FAQ

What Is the Novavax (NVAX) Stock Price Today?

The Novavax stock price today is 10.135 USD.

What Stock Exchange Does Novavax Trade On?

Novavax is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Novavax?

The stock symbol for Novavax is "NVAX."

What Is the Novavax Market Cap?

As of today, Novavax market cap is 1.630B USD.

What Is Novavax's Earnings Per Share (TTM)?

The Novavax EPS (TTM) is 2.720.

When Is the Next Novavax Earnings Date?

Novavax will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is NVAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Novavax Stock Split?

Novavax has split 1 times.

How Many Employees Does Novavax Have?

Novavax has 952 employees.

What is the current trading status of Novavax (NVAX)?

As of Feb 28, 2026, Novavax (NVAX) is trading at a price of 10.135 USD, with a previous close of 11.190 USD. The stock has fluctuated within a day range of 9.810 USD to 11.150 USD, while its 52-week range spans from 5.010 USD to 11.970 USD.

What Is Novavax (NVAX) Price Target According to Analysts?

The average 12-month price target for Novavax is 13.000 USD, with a high estimate of 25 USD and a low estimate of 6 USD. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +28.27% Upside potential.

What Is the NVAX After Hours Price?

NVAX's last after hours stock price is 10.080 USD, the stock has decreased by -0.060, or -0.590%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.